Table 1. Clinical characteristics of breast cancer patients with TMA.
| Features | NOP14 low expression | NOP14 high expression | P-value |
|---|---|---|---|
| Age(years) | |||
| ≤40 | 35 | 42 | 0.7 |
| >40 | 139 | 147 | |
| Tumor grade | |||
| 1 | 30 | 33 | 0.971 |
| 2 | 96 | 102 | |
| 3 | 48 | 54 | |
| Tumor size | |||
| T1 (≤2 cm) | 49 | 57 | 0.906 |
| T2 (>2 cm, ≤5 cm) | 112 | 119 | |
| T3 (>5 cm) | 13 | 13 | |
| Lymph node status | |||
| 0 | 82 | 95 | 0.402 |
| 1–3 | 48 | 49 | |
| 4–9 | 23 | 31 | |
| >9 | 21 | 14 | |
| Stage | |||
| I-II | 126 | 135 | 0.907 |
| III | 48 | 54 | |
| ER status | |||
| Positive | 63 | 91 | 0.026 |
| Negative | 111 | 98 | |
| PR status | |||
| Positive | 57 | 87 | 0.01 |
| Negative | 117 | 102 | |
| HER2 status | |||
| Positive | 50 | 58 | 0.731 |
| Negative | 124 | 131 | |
| Ki67 | |||
| >14% | 87 | 98 | 0.753 |
| ≤14% | 87 | 91 | |
| Menstrual status | |||
| Premenopausal | 72 | 68 | 0.332 |
| Postmenopausal | 102 | 121 |
ER, estrogen receptor; PR, progesterone receptor;HER2, human epidermal growth factor receptor 2